Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

MSCL.TO Relative to the S&P 500

MSCL.TO Relative to the Sector

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the Satellos Bioscience Inc. (TSE:MSCL.TO) seasonal charts above shows that a Buy Date of December 23 and a Sell Date of March 13 has resulted in a geometric average return of 8.73% above the benchmark rate of the S&P 500 Total Return Index over the past 17 years. This seasonal timeframe has shown positive results compared to the benchmark in 11 of those periods. This is a fair rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 17 years by an average of 31.2% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX and Leveraging MyoReGenX , which identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki on July 27, 2012 and is headquartered in Toronto, Canada.

To download MSCL.TO seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: MSCL.TO